Small Molecules

06 Jun 2023 OrsoBio Announces Phase 1 Trial of TLC-6740, a Mitochondrial Protonophore for the Treatment of Obesity and Associated Diseases
05 Jun 2023 Statement: Biogen Provides Update on Parkinson’s Disease Clinical Development Program
05 Jun 2023 BenevolentAI Progresses BEN-34712 for the Potential Treatment of ALS into IND-Enabling Studies
04 Jun 2023 TAGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial
04 Jun 2023 Intensity Therapeutics' INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas
02 Jun 2023 Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options
02 Jun 2023 Bayer starts phase II/III study with vericiguat in children with heart failure
01 Jun 2023 Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2b Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction
01 Jun 2023 Lynparza plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
01 Jun 2023 Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology
31 May 2023 C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC
31 May 2023 Debiopharm launches phase 1 research in small cell lung cancer with Wee1 inhibitor Debio 0123 to outsmart DDR in small cell lung cancer
31 May 2023 Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus
29 May 2023 AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer
27 May 2023 Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure
26 May 2023 Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity
26 May 2023 Pfizer’s PAXLOVID™ Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19
26 May 2023 Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting
25 May 2023 BIAL R&D Announces First Patient Dosed in its Phase 2 Clinical Trial of BIA 28-6156 to Treat Parkinson's Disease Patients With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene
24 May 2023 AnaMar Announces Positive Phase I Data for its Phase II Ready Compound AM1476 for Treating Fibrosis
24 May 2023 NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics study of NMD1343
24 May 2023 Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases
24 May 2023 Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis
24 May 2023 Cumberland Pharmaceuticals announces FDA clearance of IND for new treatment of idiopathic pulmonary fibrosis
24 May 2023 TrialSpark Announces First Patient Dosed in Phase 2 Clinical Trial for ASN008-201 in Atopic Dermatitis

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up